Detalles de la búsqueda
1.
Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin.
Breast Cancer Res Treat
; 202(3): 575-583, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37733188
2.
Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in 18F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy.
Ann Surg Oncol
; 26(7): 2175-2183, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30941655
3.
High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy.
J Surg Oncol
; 118(1): 228-237, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29936704
4.
Total Lesion Glycolysis Levels as Predictive Indicators in Patients With Metastatic and Recurrent Breast Cancer Undergoing Endocrine Therapy With or Without CDK4/6 Inhibitor.
Anticancer Res
; 42(10): 4813-4824, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36191999
5.
Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
Anticancer Res
; 42(10): 4867-4878, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36192009
6.
Prognostic Significance of Neutrophil-to-lymphocyte Ratio in Luminal Breast Cancers With Low Levels of Tumour-infiltrating Lymphocytes.
Anticancer Res
; 40(5): 2871-2880, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32366437
7.
Association Between FOXP3/CD8 Lymphocyte Ratios and Tumor Infiltrating Lymphocyte Levels in Different Breast Cancer Subtypes.
Anticancer Res
; 40(4): 2141-2150, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32234907
8.
C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin.
Anticancer Res
; 40(7): 4147-4156, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32620664
9.
Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer.
Oncotarget
; 11(1): 86-98, 2020 Jan 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32002126
10.
Improved prognosis of low baseline neutrophil-to-lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes.
Mol Clin Oncol
; 10(2): 275-284, 2019 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-30680208
11.
A Single-centre, Retrospective, Observational Analysis of Fulvestrant for Recurrent/metastatic Breast Cancer According to Metastatic Site.
Anticancer Res
; 39(10): 5653-5662, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31570463
12.
Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine.
Sci Rep
; 9(1): 1811, 2019 02 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30755651
13.
Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
Breast Cancer
; 26(6): 738-747, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31098866
14.
Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.
Clin Breast Cancer
; 18(5): 400-409, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29605174
Resultados
1 -
14
de 14
1
Próxima >
>>